{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:26Z","timestamp":1792712186676,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02940-w","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:44:00Z","timestamp":1765298640000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sustained antiemetic efficacy of fosnetupitant versus aprepitant in carboplatin-based chemotherapy: a retrospective observational study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-9822","authenticated-orcid":false,"given":"Hiroshi","family":"Inano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-0614","authenticated-orcid":false,"given":"Yoshihito","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Niizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanata","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Anzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2940_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.34067\/KID.0000000000000349","volume":"5","author":"MH Schwenk","year":"2024","unstructured":"Schwenk MH (2024) Carboplatin dosing on the basis of renal function: 30+ years after Calvert. Kidney360 5:271\u2013273. https:\/\/doi.org\/10.34067\/KID.0000000000000349","journal-title":"Kidney360"},{"key":"2940_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"2940_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"2940_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491\u2013497. https:\/\/doi.org\/10.1007\/s10147-015-0928-y","journal-title":"Int J Clin Oncol"},{"key":"2940_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-021-00204-z","volume":"7","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Saito Y, Mitamura T et al (2021) Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. J Pharm Health Care Sci 7:21. https:\/\/doi.org\/10.1186\/s40780-021-00204-z","journal-title":"J Pharm Health Care Sci"},{"key":"2940_CR6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s10147-024-02623-y","volume":"29","author":"T Hayashi","year":"2024","unstructured":"Hayashi T, Yamamoto S, Miyata Y et al (2024) Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology. Int J Clin Oncol 29:1616\u20131631. https:\/\/doi.org\/10.1007\/s10147-024-02623-y","journal-title":"Int J Clin Oncol"},{"key":"2940_CR7","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.21873\/invivo.13704","volume":"38","author":"S Nishibe-Toyosato","year":"2024","unstructured":"Nishibe-Toyosato S, Ando Y, Torii Y et al (2024) Comparing injection site reactions of aprepitant and fosaprepitant in gynecologic cancer chemotherapy. In Vivo 38:2374\u20132382. https:\/\/doi.org\/10.21873\/invivo.13704","journal-title":"In Vivo"},{"key":"2940_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N et al (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40:180\u2013188. https:\/\/doi.org\/10.1200\/JCO.21.01315","journal-title":"J Clin Oncol"},{"key":"2940_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1248\/bpb.b23-00819","volume":"47","author":"H Inano","year":"2024","unstructured":"Inano H, Morimoto Y, Kitagawa K et al (2024) Comparing the efficacy of fosnetupitant, an NK1 receptor antagonist in CDDP-based regimens, with that of fosaprepitant and aprepitant: a retrospective observational study. Biol Pharm Bull 47:692\u2013697. https:\/\/doi.org\/10.1248\/bpb.b23-00819","journal-title":"Biol Pharm Bull"},{"key":"2940_CR10","unstructured":"Drugs Pharmaceuticals and Medical Devices Agency (2023) Package Inserts of Prescription; Aprepitant version 1.2023. https:\/\/www.info.pmda.go.jp\/go\/pack\/2391008M1030_1_02\/?view=frame&style=XML&lang=ja. Accessed Aug 10, 2025"},{"key":"2940_CR11","unstructured":"Drugs Pharmaceuticals and Medical Devices Agency (2022) Package Inserts of Prescription; Arokaris version 2. 2022. https:\/\/www.info.pmda.go.jp\/go\/pack\/2391406A1029_1_02\/?view=frame&style=XML&lang=ja. Accessed Aug 10, 2025"},{"key":"2940_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40266-021-00909-8","volume":"39","author":"J Herrstedt","year":"2022","unstructured":"Herrstedt J, Lindberg S, Petersen PC (2022) Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes. Drugs Aging 39:1\u201321. https:\/\/doi.org\/10.1007\/s40266-021-00909-8","journal-title":"Drugs Aging"},{"key":"2940_CR13","unstructured":"Drugs Pharmaceuticals and Medical Devices Agency (2025) Package inserts of prescription; Carboplatin version 6. 2025. https:\/\/www.info.pmda.go.jp\/go\/pack\/4291403A1088_3_02\/?view=frame&style=XML&lang=ja. Accessed Sep 13, 2025"},{"key":"2940_CR14","first-page":"1299","volume":"7","author":"DA Spandidos","year":"1987","unstructured":"Spandidos DA, Pintzas A, Kakkanas A et al (1987) Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299\u20131304","journal-title":"Anticancer Res"},{"key":"2940_CR15","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1007\/s12325-023-02648-1","volume":"40","author":"N Inui","year":"2023","unstructured":"Inui N, Toi Y, Yoneshima Y et al (2023) Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase. Adv Ther 40:4928\u20134944. https:\/\/doi.org\/10.1007\/s12325-023-02648-1","journal-title":"Adv Ther"},{"key":"2940_CR16","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"key":"2940_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jcph.198","volume":"54","author":"T Spinelli","year":"2014","unstructured":"Spinelli T, Calcagnile S, Giuliano C et al (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54:97\u2013108. https:\/\/doi.org\/10.1002\/jcph.198","journal-title":"J Clin Pharmacol"},{"key":"2940_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0091270007301800","volume":"47","author":"KC Lasseter","year":"2007","unstructured":"Lasseter KC, Gambale J, Jin B et al (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834\u2013840. https:\/\/doi.org\/10.1177\/0091270007301800","journal-title":"J Clin Pharmacol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02940-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:07:46Z","timestamp":1769486866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02940-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02940-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7701613\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Kitasato University Hospital (approval number: B24-048) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained through an opt-out procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}